Developer docs
API playgroundTry for free, no card

Search company profiles

Colossal Biosciences

Full company profile

uuid0000081

Namestring
Colossal Biosciences
Legal namestring
Colossal Biosciences Inc.
Websiteurl
colossal.com
Company typeenum
Private
Founded yearint
2021
Descriptiontext

Colossal Biosciences is a Dallas-headquartered biotechnology company founded in 2021 by entrepreneur Ben Lamm and Harvard geneticist George Church. The company pursues what it calls "functional de-extinction" of six extinct or lost species (woolly mammoth, thylacine, dodo, dire wolf, South Island giant moa, and bluebuck) using an integrated stack that combines CRISPR/Cas9 genome editing, ancient DNA assembly, comparative genomics, AI/machine learning, stem cell reprogramming (iPSCs and primordial germ cell culture), embryology, and exogenous (artificial womb) development. It extends the same toolkit into conservation of currently threatened species, including genetic-rescue cloning of red 'ghost' wolves, mRNA vaccines for elephant endotheliotropic herpesvirus, AI-driven bioacoustic monitoring, and global BioVault cryopreservation programs.

The company's product surface spans six flagship de-extinction programs, the 3D-printed artificial egg system, the Colossal BioVault network (10,000+ species targeted in Dubai and 2,300+ ESA-listed species in a U.S. partnership), wildlife-disease programs (EEHV mRNA vaccine, New World Screwworm gene drive), and AI bioacoustic monitoring. Operating entities include the wholly owned Viagen Pets & Equine cloning subsidiary (acquired November 2025, ~$50,000 per pet clone), the Astromech AI subsidiary (over $2B valuation in nine months), Form Bio, and the nonprofit Colossal Foundation (over $100M in conservation funding). The business is venture-backed: cumulative disclosed funding exceeds $615M across seed, Series A, Series B, and a multi-tranche Series C led by TWG Global in April 2025 at approximately $10.2-$10.3B valuation. Customers include the UAE government, the U.S. Fish and Wildlife Service, the Mauritian Wildlife Foundation, the Ngāi Tahu Research Centre, the Endangered Wildlife Trust, Baylor College of Medicine, multiple conservation NGOs and zoos, and high-net-worth individual pet-cloning buyers (e.g., Tom Brady, Paris Hilton, Barbra Streisand).

Go-to-market mixes direct enterprise and government contracting for BioVault programs, channel/NGO partnerships for conservation delivery, an OEM-style co-development model for flagship de-extinction species, and a direct-to-consumer pet cloning arm via Viagen. Distribution and capital are augmented by deep PR-driven earned media (Time, Wired, NPR, Smithsonian, MIT Technology Review) and celebrity investor amplification, while scientific credibility is anchored by a Scientific Advisory Board that includes Nobel laureate Carolyn Bertozzi and a senior leadership team drawn from Harvard, MIT, UC Santa Cruz, Princeton, and the University of Melbourne.

Short descriptiontext

Colossal Biosciences is a Dallas-based biotechnology company that uses CRISPR, ancient DNA, AI, and reproductive biology to pursue functional de-extinction of six species and to deliver genetic-rescue, BioVault, and cloning services to governments, conservation NGOs, zoos, and high-net-worth pet owners.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
251–500
akta.pro rankint
HeadquartersAustin, United States
HQ citystring
Austin
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
de-extinction services, genetic engineering, genome editing, wildlife conservation, animal cloning
Industry3 codes
PRIMARYHLAAAIAD
Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAMANAJ
Cryopreservation, Biobanking & Cell Banking (Cord/Adipose/MSC)
Healthcare & Life Sciences/Veterinary & Animal Health/Regenerative Medicine for Animals
SECONDARYAFAEAJAL
Cloning & Advanced Reproductive Technologies Services
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Biotechnology
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model5 records
1Commercial Pet Cloning Services
TypeTransaction Fee
Description

Direct-to-consumer pet cloning sold through the wholly owned Viagen Pets & Equine subsidiary, priced at roughly $50,000 per clone, with celebrity customers including Tom Brady, Paris Hilton and Barbra Streisand driving awareness and revenue.

economictimes.indiatimes.com
2Spinout Subsidiary Revenue
TypeSubscription Recurring
Description

Current revenue coming from spinout ventures in computational biology and recycling technologies, including the AI-focused subsidiary Astromech, which reached a $2B+ valuation within nine months.

economictimes.indiatimes.com
3Government BioVault Contracts
TypeManaged Services
Description

Large multi-year institutional deals such as the $60M UAE BioVault at Dubai's Museum of the Future and the U.S. Fish & Wildlife Service agreement covering 2,300+ ESA-listed species, functioning as multi-year service contracts.

dallasinnovates.com
4Conservation Technology Licensing & Partnerships
TypeLicensing Royalties
Description

Monetization of de-extinction-derived tools (e.g., mRNA EEHV elephant vaccine developed with Baylor College of Medicine and the Houston Zoo, bioacoustic monitoring) deployed through conservation partners and zoos.

colossal.com
5Venture Funding & Equity Capital
TypeSubscription Recurring
Description

Capital raised from VCs, strategic investors and celebrity backers across seed, Series A, Series B and Series C rounds, totaling roughly $435M-$615M depending on the reporting period and the $200M Series C led by TWG Global.

inc.com
Marketing channels9 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels6 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure, Supply Chain
Pricing details3 tiers
1Pet cloning via Viagen Pets & Equine subsidiary
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Approximately $50,000 per cloned pet, illustrated by Tom Brady cloning his late dog Lua via a pre-death blood sample.

dallasnews.com
2Government / institutional BioVault programs (UAE, USFWS)
ModelOtherBilling cadenceMulti-year contract
Notes

Nine-figure investment in the UAE-led BioVault program covering over 10,000 species; Colossal also selected Dubai as its first BioVault site under a $60M partnership with the UAE.

dallasinnovates.com
3Accredited-investor private market allocations via SoFi/Templum
ModelOtherBilling cadencePay-as-you-go
Notes

Limited-time private offering window for Colossal Biosciences stock available to accredited investors between March 5-30, 2026 as part of the Templum/SoFi Cosmos Fund alongside Perplexity AI and OpenAI.

stocktitan.net
GTM typeB2B and B2C
B2B and B2C
Offering typeServices
Services
Brand1 of 3 records shown
1The Colossal Foundation
Description

Nonprofit arm of Colossal Biosciences focused on funding conservation projects, cloning red wolves, developing wildlife disease vaccines, and preventing mass extinctions. Doubled its funding to $100 million in December 2025.

prnewswire.com
+2 more records
Core offering1 text field

Colossal Biosciences is a biotechnology company that uses CRISPR-based genetic engineering, ancient DNA assembly, stem cell reprogramming, and reproductive biology to pursue 'functional de-extinction' of lost species (woolly mammoth, thylacine, dodo, dire wolf, moa, bluebuck) while applying the same toolkit to conservation of living endangered species. It monetizes through government BioVault contracts, conservation technology licensing, the Viagen pet cloning subsidiary, and the Astromech AI spinout.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Colossal Biosciences operates a platform-plus-modules architecture anchored by six flagship de-extinction projects (Woolly Mammoth, Thylacine, Dodo, Dire Wolf, South Island Giant Moa, and Bluebuck), each applying CRISPR, ancient DNA assembly, comparative genomics, stem cell reprogramming (iPSCs), primordial germ cell (PGC) culture, and embryology. Underpinning these projects are six enabling technology focus areas — Genetic Engineering, AI & Machine Learning, Embryology, Stem Cell Reprogramming, Conservation & Animal Husbandry, and Exogenous Development — plus reproductive hardware such as the 3D-Printed Artificial Egg System. The platform extends outward into a global genetic preservation network (the Colossal BioVault, with sites in Dubai and a partnership with the U.S. Fish and Wildlife Service), wildlife-disease programs (Elephant EEHV mRNA Vaccine), invasive-species control (New World Screwworm Gene Drive), AI bioacoustic monitoring, and conservation cloning through the acquired Viagen Pets & Equine subsidiary. Spinoff commercialization occurs through Astromech (AI subsidiary, $2B+ valuation), Form Bio, and the nonprofit Colossal Foundation (with $100M in conservation funding).

Product and service15 records
1Woolly Mammoth De-Extinction Program
CategoryFlagship de-extinction project
Description

Resurrection of the woolly mammoth (Mammuthus primigenius) as a cold-resistant elephant hybrid carrying core mammoth traits. Colossal is editing Asian elephant DNA to introduce mammoth traits (cold resistance, thicker hair) using CRISPR, with first calves targeted for 2028 and rewilding aimed at restoring Arctic tundra ecosystems.

2Thylacine (Tasmanian Tiger) De-Extinction Program
CategoryFlagship de-extinction project
Description

De-extinction of the thylacine (Thylacinus cynocephalus), a large carnivorous marsupial extinct since 1936, in partnership with the University of Melbourne and the TIGRR Lab. Program consolidated under Colossal Australia and includes Northern quoll cane toad resistance research.

3Dodo De-Extinction Program
CategoryFlagship de-extinction project
Description

Effort to bring back the dodo (Raphus cucullatus), extinct since the late 17th century on Mauritius, in partnership with the Mauritian Wildlife Foundation. Includes the world's first successful culturing of pigeon primordial germ cells (PGCs), dodo genome sequencing, and a Mauritius Dodo Advisory Committee.

4Dire Wolf De-Extinction Program
CategoryFlagship de-extinction project
Description

Production of three living dire wolf pups (Romulus, Remus, Khaleesi) via 20 targeted genetic edits across 14 genes in the gray wolf genome using ancient DNA from 13,000-year-old and 72,000-year-old specimens. Animals live at a 2,000-acre secure ecological preserve.

5South Island Giant Moa De-Extinction Program
CategoryFlagship de-extinction project
Description

Strategic partnership with the Ngāi Tahu Research Centre, Canterbury Museum, and Sir Peter Jackson to revive the South Island giant moa (Dinornithiformes) using genetic engineering, primordial germ cell culture, and interspecies surrogacy with tinamous and emus.

6Bluebuck De-Extinction Program
CategoryFlagship de-extinction project
Description

Sixth species added to the de-extinction portfolio; first African species and first antelope. Uses a 40-fold high-coverage paleogenome from a 226-year-old museum specimen, with roan antelope as genetic reference and surrogate.

7Colossal BioVault
CategoryGenetic preservation platform
Description

Global network of cryopreserved genetic repositories for endangered and extinct species. Flagship site at Dubai's Museum of the Future (UAE partnership, $60M) houses samples from 10,000+ species with automated robotics, AI monitoring, and cryopreservation. A separate USFWS partnership covers 2,300+ threatened/endangered U.S. species.

8Viagen Pets & Equine (Pet Cloning Service)
CategoryAcquired subsidiary / cloning services
Description

Texas-based animal cloning company acquired by Colossal in November 2025. Operates as a wholly owned subsidiary offering pet, equine, and livestock cloning (e.g., Tom Brady's cloned dog Junie). Has cloned 15 species and preserved genetic material from over 40 species.

9Astromech (AI Subsidiary)
CategoryAI-focused subsidiary / spinout
Description

AI-focused Colossal subsidiary launched to commercialize computational biology and AI capabilities spun out from Colossal's R&D. Reached unicorn status with a valuation exceeding $2 billion in nine months.

10Artificial Egg System (3D-Printed Shell-less Egg)
CategoryReproductive technology module
Description

Fully artificial shell-less egg system using a 3D-printed lattice shell with a bioengineered silicone-based membrane that matches natural eggshell oxygen transfer. Successfully hatched 26 chicks as proof of concept; scalable for eggs of any size.

11Elephant EEHV mRNA Vaccine Program
CategoryWildlife disease / conservation therapeutics
Description

Partnership with Baylor College of Medicine and the Houston Zoo to develop an mRNA vaccine for elephant endotheliotropic herpesvirus (EEHV). The vaccine successfully saved two vaccinated young elephants at the Cincinnati Zoo.

12Red 'Ghost' Wolf Cloning & Genetic Rescue Program
CategoryConservation cloning / genetic rescue
Description

Cloning of red wolves from blood samples of Gulf Coast 'ghost canids' carrying ancestral red wolf DNA, led by the Colossal Foundation in coalition with the Gulf Coast Canine Project. Clones could add 25% more diversity to red wolf breeding programs.

13AI-Powered Bioacoustic Monitoring
CategoryConservation technology product
Description

AI-driven bioacoustic monitoring programs deployed in Yellowstone (gray wolves), Samburu (African elephants), and Samoa (tooth-billed pigeon) for passive conservation monitoring, species identification, and behavior analysis.

14Form Bio
CategorySoftware / spinout
Description

Software/wetware/hardware spinout company referenced on Colossal's technology page, part of the platform's commercialization track parallel to the de-extinction focus areas.

15New World Screwworm Gene Drive Program
CategoryInvasive species control / regulatory pipeline
Description

Gene drive technology engineered to produce infertile female screwworms and spread through wild populations until collapse; proposed as a faster alternative to sterile insect technique for eliminating the flesh-eating parasite that threatens U.S. livestock. Currently unapproved for open release.

Scale indicator14 records

Each record includes

Type, Value, Description, Source

Partnership38 partners
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2026-06-25
Description

Partnership with the Colossal Foundation to create a genetic biobank for over 2,300 threatened and endangered species under the Endangered Species Act, with the Colossal Foundation committing $100M+ and making all genomic data freely available via open-access repositories.

Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2026-06-25
Description

Colossal's nonprofit arm with $100M+ in donations since late 2024, deploying Colossal's technologies to partner-led conservation initiatives including the USFWS BioVault and the Samoa Conservation Society partnership.

3Quantum XChange
Strategic tierMinorTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-05-01
Description

Colossal listed among Quantum XChange's strategic partners for post-quantum cryptography alongside Copper River, Data Wide, Evolutio, GovSmart, Iron Bow and World Wide Technology.

einpresswire.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-04-30
Description

South African conservation partner conducting ecological planning, stakeholder engagement and feasibility studies for potential bluebuck reintroduction and broader antelope conservation.

Strategic tierCoreTypeImplementation/ SI/ Consulting PartnerAnnounced on2026-04-30
Description

Partner on bluebuck and broader antelope conservation, contributing ecological planning and feasibility work alongside the Endangered Wildlife Trust.

Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2026-04-03
Description

Colossal's AI-focused subsidiary that reached unicorn status with a $2B+ valuation in nine months and raised $10.5M per bizjournals, serving as a commercial AI spinout of Colossal's platform.

Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2026-02-03
Description

Nine-figure partnership (including a $60M investment tranche) to build the Colossal BioVault and World Preservation Lab at Dubai's Museum of the Future, preserving genetic material from over 10,000 species with plans to expand into a global network of 10+ interconnected BioVaults.

Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2025-11-06
Description

Acquired by Colossal in November 2025 to integrate reproductive services, cryopreservation and cell banking into its conservation platform; operates as a wholly owned subsidiary continuing its pet, equine and livestock services while partnering on endangered-species programs and BioVaults.

Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2025-08-21
Description

Academic partner for the thylacine de-extinction program since 2025 via the new Colossal Australia entity; hosts the TIGRR Lab led by Chief Biology Officer Andrew Pask.

10Ngāi Tahu Research Centre
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2025-07-11
Description

Strategic partnership directing the South Island giant moa de-extinction program with Peter Jackson and Colossal; the principal Māori research hub of New Zealand's South Island leads rather than merely advises on the project, integrating cultural perspectives.

businesswire.com
11Canterbury Museum
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-07-11
Description

Provides access to the world's largest moa bone collection, supplying ancient DNA for the South Island giant moa de-extinction program.

businesswire.com
12Samoa Conservation Society
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-05-29
Description

Partner for AI-driven bioacoustic search to find the critically endangered tooth-billed pigeon (manumea) in Samoa; led by the Colossal Foundation.

businesswire.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-11-21
Description

Partnership to rewild the dodo to its native habitat, with the MWF helping to protect critically-endangered avian species on Mauritius and laying groundwork for the dodo's eventual reintroduction.

Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2023-09-01
Description

Colossal joined BioRescue in its mission to save the northern white rhino from extinction, sequencing all known viable and preserved museum samples to identify lost genetic diversity that can be engineered into cell lines for embryo transfer.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-07-01
Description

Co-developed the mRNA vaccine for elephant endotheliotropic herpesvirus (EEHV) that saved two young elephants at the Cincinnati Zoo; longstanding academic partner on elephant conservation.

16Elephant Havens
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-07-01
Description

Partnership to develop new models for the successful reintroduction of orphaned elephants using AI; the only elephant orphanage in Botswana using Colossal's AI platform.

colossal.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-01-01
Description

Uses Colossal's AI and drones to study elephants in Samburu National Park, training AI to identify individuals, herds and behaviors and to predict behavior to mitigate Human-Elephant Conflict.

Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2023-01-01
Description

Directed by Sheikh Hamdan bin Mohammed bin Rashid Al Maktoum to become the permanent home of the World Preservation Lab and BioVault, a biotechnology initiative developed in collaboration with Colossal Biosciences.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2022-01-01
Description

Australian conservation partner supporting marsupial conservation and Tasmanian devil reintroduction.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2022-01-01
Description

Conservation partner contributing to Tasmanian devil reintroduction into mainland Australia and broader rewilding programs.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2022-01-01
Description

Australian conservation partner supporting Tasmania thylacine and broader biodiversity initiatives; Chris Hemsworth cited WildArk as a partner he is excited to support.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2022-01-01
Description

Tasmanian wildlife sanctuary partner supporting Tasmanian devil conservation and rewilding.

23Southeast Zoo Alliance for Reproduction & Conservation (SEZARC)
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2022-01-01
Description

Florida-based reproductive science alliance led by Linda Penfold, contributing expertise in assisted reproduction for endangered species.

colossal.com
24Pronatura Noroeste
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2022-01-01
Description

Latin American conservation partner supporting regional biodiversity programs.

colossal.com
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2022-01-01
Description

Conservation partner hosting Colossal's AI-powered bioacoustic monitoring program for gray wolves in Yellowstone.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2022-01-01
Description

Global avian conservation partner supporting dodo and broader pigeon conservation programs.

27IUCN SSC Pigeon and Dove Specialist Group
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2022-01-01
Description

Specialist conservation partner supporting avian genomics and dodo de-extinction work.

colossal.com
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2022-01-01
Description

Conservation partner supporting the northern white rhino genetic rescue program.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2022-01-01
Description

Academic consortium providing reference genome resources for Colossal's comparative genomics and de-extinction programs.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2022-01-01
Description

Conservation partner for wolf conservation messaging and outreach; also publicly critiqued Colossal's red wolf cloning approach.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2022-01-01
Description

Ancient DNA research partner providing radiocarbon dating and ancient DNA analysis of mammoth and other Pleistocene fossils housed at the University of Alaska Museum of the North.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2022-01-01
Description

Ancient DNA academic partner receiving Colossal funding for deep-time genomic research on North American Columbian mammoths, Pygmy mammoths and megafauna such as giant ground sloths, glyptodonts and pampatheres.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2022-01-01
Description

Ancient DNA academic partner including high-coverage genomes of extinct species and chromosome-scale assemblies of living relatives, plus research on cave hyenas.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2022-01-01
Description

Partner with Professor Love Dalén studying ancient DNA of extinct species including bluebuck, straight-tusked elephant and other recently extinct animals to understand the extinction process.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2022-01-01
Description

Dr. Michael Hofreiter leads Colossal-funded genome sequencing of extinct species such as bluebuck and the straight-tusked elephant at the Institute for Biochemistry and Biology.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2022-01-01
Description

Academic partner (Kenneth Lacovara) unlocking ancient proteins and biomolecules from fossils to study extinct creatures.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2022-01-01
Description

Beth Shapiro-led paleogenomics research partnership, supported by Colossal donations.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2022-01-01
Description

Indigenous partner for red wolf conservation, honoring the cultural and spiritual significance of the wolf as a clan animal.

Recent move9 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Synthetic DNA and genomics products company whose DNA synthesis and NGS products underpin much of the synthetic biology ecosystem, including ancient DNA reconstruction pipelines similar to Colossal's reference genome work.

TypeEmerging player
Description

AI-driven biotech combining high-throughput biology with machine learning. Comparable to Colossal's Astromech subsidiary as a biology + AI platform company pursuing large, multi-program pipelines.

TypeOthers
Description

Consumer genetics company with a large proprietary genotype/phenotype database. Thematically comparable to Colossal in combining large-scale genomics, AI and consumer-facing storytelling, though operating in human rather than animal genetics.

TypeOthers
Description

Conservation technology incubator and grand-prize challenge sponsor focused on ending the sixth mass extinction. Adjacent to Colossal's mission and a potential partner/customer in conservation tech rather than a direct competitor.

TypeBroad incumbent
Description

Clinical-stage gene editing company co-founded by Emmanuelle Charpentier, applying CRISPR/Cas9 to human therapeutics. A broad incumbent in the same underlying CRISPR platform technology that Colossal uses for de-extinction.

TypeDirect peer
Description

The leading nonprofit dedicated to de-extinction and genetic rescue, working on the passenger pigeon, northern white rhino, and Przewalski's horse. It is the closest direct peer to Colossal's mission and uses similar CRISPR and ancient DNA tooling.

TypeEmerging player
Description

Gene editing company applying CRISPR to xenotransplantation (gene-edited pig organs for human transplant). Directly comparable on CRISPR platform technology and on the integration of genome editing with reproductive biology.

TypeBroad incumbent
Description

Large synthetic biology platform company offering cell engineering and biofoundry services. Comparable to Colossal as a platform biotech commercializing engineered biology, though focused on industrial organisms rather than de-extinction.

TypeEmerging player
Description

Clinical-stage gene editing company developing in vivo CRISPR-based cardiovascular therapies. Comparable to Colossal on the underlying CRISPR platform and on its positioning around 'rewriting' biology for a defined outcome.

TypeEmerging player
Description

CRISPR-based biotech co-founded by Jennifer Doudna developing CRISPR diagnostics and gene-editing therapies. Comparable to Colossal as a CRISPR platform company, though focused on human health rather than animal de-extinction.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat7 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers14 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile5 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability5 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature9 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles16 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries4 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds8 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors33 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment3 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Colossal Biosciences

Biotechnologycolossal.com

Colossal Biosciences is a Dallas-based biotechnology company that uses CRISPR, ancient DNA, AI, and reproductive biology to pursue functional de-extinction of six species and to deliver genetic-rescue, BioVault, and cloning services to governments, conservation NGOs, zoos, and high-net-worth pet owners.

What Colossal Biosciences does

Colossal Biosciences is a Dallas-headquartered biotechnology company founded in 2021 by entrepreneur Ben Lamm and Harvard geneticist George Church. The company pursues what it calls "functional de-extinction" of six extinct or lost species (woolly mammoth, thylacine, dodo, dire wolf, South Island giant moa, and bluebuck) using an integrated stack that combines CRISPR/Cas9 genome editing, ancient DNA assembly, comparative genomics, AI/machine learning, stem cell reprogramming (iPSCs and primordial germ cell culture), embryology, and exogenous (artificial womb) development. It extends the same toolkit into conservation of currently threatened species, including genetic-rescue cloning of red 'ghost' wolves, mRNA vaccines for elephant endotheliotropic herpesvirus, AI-driven bioacoustic monitoring, and global BioVault cryopreservation programs.

The company's product surface spans six flagship de-extinction programs, the 3D-printed artificial egg system, the Colossal BioVault network (10,000+ species targeted in Dubai and 2,300+ ESA-listed species in a U.S. partnership), wildlife-disease programs (EEHV mRNA vaccine, New World Screwworm gene drive), and AI bioacoustic monitoring. Operating entities include the wholly owned Viagen Pets & Equine cloning subsidiary (acquired November 2025, ~$50,000 per pet clone), the Astromech AI subsidiary (over $2B valuation in nine months), Form Bio, and the nonprofit Colossal Foundation (over $100M in conservation funding). The business is venture-backed: cumulative disclosed funding exceeds $615M across seed, Series A, Series B, and a multi-tranche Series C led by TWG Global in April 2025 at approximately $10.2-$10.3B valuation. Customers include the UAE government, the U.S. Fish and Wildlife Service, the Mauritian Wildlife Foundation, the Ngāi Tahu Research Centre, the Endangered Wildlife Trust, Baylor College of Medicine, multiple conservation NGOs and zoos, and high-net-worth individual pet-cloning buyers (e.g., Tom Brady, Paris Hilton, Barbra Streisand).

Go-to-market mixes direct enterprise and government contracting for BioVault programs, channel/NGO partnerships for conservation delivery, an OEM-style co-development model for flagship de-extinction species, and a direct-to-consumer pet cloning arm via Viagen. Distribution and capital are augmented by deep PR-driven earned media (Time, Wired, NPR, Smithsonian, MIT Technology Review) and celebrity investor amplification, while scientific credibility is anchored by a Scientific Advisory Board that includes Nobel laureate Carolyn Bertozzi and a senior leadership team drawn from Harvard, MIT, UC Santa Cruz, Princeton, and the University of Melbourne.

Colossal Biosciences firmographics

Firmographics
Name
Colossal Biosciences
Legal name
Colossal Biosciences Inc.
Website
https://colossal.com
Company type
Private
Founded year
2021
Operating status
Operating
Headcount range
251–500 employees
Short description
Colossal Biosciences is a Dallas-based biotechnology company that uses CRISPR, ancient DNA, AI, and reproductive biology to pursue functional de-extinction of six species and to deliver genetic-rescue, BioVault, and cloning services to governments, conservation NGOs, zoos, and high-net-worth pet owners.
Ownership category
akta.pro rank

Colossal Biosciences industry classification

Industry
Product category
Biotechnology
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAIAD
Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAMANAJ
Cryopreservation, Biobanking & Cell Banking (Cord/Adipose/MSC)
Healthcare & Life Sciences/Veterinary & Animal Health/Regenerative Medicine for Animals
SECONDARYAFAEAJAL
Cloning & Advanced Reproductive Technologies Services

Keywords

  • De-extinction services
  • Genetic engineering
  • Genome editing
  • Wildlife conservation
  • Animal cloning

Where Colossal Biosciences is headquartered

Location

Headquarters

HQ city
Austin
HQ country
United States
HQ region
North America

Offices4 records

Markets served

Colossal Biosciences business model

Business model
GTM type
B2B and B2C
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure, Supply Chain

Revenue model

  1. Commercial Pet Cloning Services: Direct-to-consumer pet cloning sold through the wholly owned Viagen Pets & Equine subsidiary, priced at roughly $50,000 per clone, with celebrity customers including Tom Brady, Paris Hilton and Barbra Streisand driving awareness and revenue.
  2. Spinout Subsidiary Revenue: Current revenue coming from spinout ventures in computational biology and recycling technologies, including the AI-focused subsidiary Astromech, which reached a $2B+ valuation within nine months.
  3. Government BioVault Contracts: Large multi-year institutional deals such as the $60M UAE BioVault at Dubai's Museum of the Future and the U.S. Fish & Wildlife Service agreement covering 2,300+ ESA-listed species, functioning as multi-year service contracts.
  4. Conservation Technology Licensing & Partnerships: Monetization of de-extinction-derived tools (e.g., mRNA EEHV elephant vaccine developed with Baylor College of Medicine and the Houston Zoo, bioacoustic monitoring) deployed through conservation partners and zoos.
  5. Venture Funding & Equity Capital: Capital raised from VCs, strategic investors and celebrity backers across seed, Series A, Series B and Series C rounds, totaling roughly $435M-$615M depending on the reporting period and the $200M Series C led by TWG Global.

Pricing tiers

ModelBillingPrice
Unit PricingPay-as-you-goPet cloning via Viagen Pets & Equine subsidiary
OtherMulti-year contractGovernment / institutional BioVault programs (UAE, USFWS)
OtherPay-as-you-goAccredited-investor private market allocations via SoFi/Templum

Go-to-market motion1 record

Distribution channels6 records

Marketing channels9 records

Colossal Biosciences product offering

Product offering

Core offering

Colossal Biosciences is a biotechnology company that uses CRISPR-based genetic engineering, ancient DNA assembly, stem cell reprogramming, and reproductive biology to pursue 'functional de-extinction' of lost species (woolly mammoth, thylacine, dodo, dire wolf, moa, bluebuck) while applying the same toolkit to conservation of living endangered species. It monetizes through government BioVault contracts, conservation technology licensing, the Viagen pet cloning subsidiary, and the Astromech AI spinout.

Product overview

Colossal Biosciences operates a platform-plus-modules architecture anchored by six flagship de-extinction projects (Woolly Mammoth, Thylacine, Dodo, Dire Wolf, South Island Giant Moa, and Bluebuck), each applying CRISPR, ancient DNA assembly, comparative genomics, stem cell reprogramming (iPSCs), primordial germ cell (PGC) culture, and embryology. Underpinning these projects are six enabling technology focus areas — Genetic Engineering, AI & Machine Learning, Embryology, Stem Cell Reprogramming, Conservation & Animal Husbandry, and Exogenous Development — plus reproductive hardware such as the 3D-Printed Artificial Egg System. The platform extends outward into a global genetic preservation network (the Colossal BioVault, with sites in Dubai and a partnership with the U.S. Fish and Wildlife Service), wildlife-disease programs (Elephant EEHV mRNA Vaccine), invasive-species control (New World Screwworm Gene Drive), AI bioacoustic monitoring, and conservation cloning through the acquired Viagen Pets & Equine subsidiary. Spinoff commercialization occurs through Astromech (AI subsidiary, $2B+ valuation), Form Bio, and the nonprofit Colossal Foundation (with $100M in conservation funding).

Differentiator

Problem solved

Functional benefit

Brands

  • The Colossal Foundation: Nonprofit arm of Colossal Biosciences focused on funding conservation projects, cloning red wolves, developing wildlife disease vaccines, and preventing mass extinctions. Doubled its funding to $100 million in December 2025.
  • Astromech
  • Viagen Pets & Equine

Products and services

  • Woolly Mammoth De-Extinction Program Resurrection of the woolly mammoth (Mammuthus primigenius) as a cold-resistant elephant hybrid carrying core mammoth traits. Colossal is editing Asian elephant DNA to introduce mammoth traits (cold resistance, thicker hair) using CRISPR, with first calves targeted for 2028 and rewilding aimed at restoring Arctic tundra ecosystems.
  • Thylacine (Tasmanian Tiger) De-Extinction Program De-extinction of the thylacine (Thylacinus cynocephalus), a large carnivorous marsupial extinct since 1936, in partnership with the University of Melbourne and the TIGRR Lab. Program consolidated under Colossal Australia and includes Northern quoll cane toad resistance research.
  • Dodo De-Extinction Program Effort to bring back the dodo (Raphus cucullatus), extinct since the late 17th century on Mauritius, in partnership with the Mauritian Wildlife Foundation. Includes the world's first successful culturing of pigeon primordial germ cells (PGCs), dodo genome sequencing, and a Mauritius Dodo Advisory Committee.
  • Dire Wolf De-Extinction Program Production of three living dire wolf pups (Romulus, Remus, Khaleesi) via 20 targeted genetic edits across 14 genes in the gray wolf genome using ancient DNA from 13,000-year-old and 72,000-year-old specimens. Animals live at a 2,000-acre secure ecological preserve.
  • South Island Giant Moa De-Extinction Program Strategic partnership with the Ngāi Tahu Research Centre, Canterbury Museum, and Sir Peter Jackson to revive the South Island giant moa (Dinornithiformes) using genetic engineering, primordial germ cell culture, and interspecies surrogacy with tinamous and emus.
  • Bluebuck De-Extinction Program Sixth species added to the de-extinction portfolio; first African species and first antelope. Uses a 40-fold high-coverage paleogenome from a 226-year-old museum specimen, with roan antelope as genetic reference and surrogate.
  • Colossal BioVault Global network of cryopreserved genetic repositories for endangered and extinct species. Flagship site at Dubai's Museum of the Future (UAE partnership, $60M) houses samples from 10,000+ species with automated robotics, AI monitoring, and cryopreservation. A separate USFWS partnership covers 2,300+ threatened/endangered U.S. species.
  • Viagen Pets & Equine (Pet Cloning Service) Texas-based animal cloning company acquired by Colossal in November 2025. Operates as a wholly owned subsidiary offering pet, equine, and livestock cloning (e.g., Tom Brady's cloned dog Junie). Has cloned 15 species and preserved genetic material from over 40 species.
  • Astromech (AI Subsidiary) AI-focused Colossal subsidiary launched to commercialize computational biology and AI capabilities spun out from Colossal's R&D. Reached unicorn status with a valuation exceeding $2 billion in nine months.
  • Artificial Egg System (3D-Printed Shell-less Egg) Fully artificial shell-less egg system using a 3D-printed lattice shell with a bioengineered silicone-based membrane that matches natural eggshell oxygen transfer. Successfully hatched 26 chicks as proof of concept; scalable for eggs of any size.
  • Elephant EEHV mRNA Vaccine Program Partnership with Baylor College of Medicine and the Houston Zoo to develop an mRNA vaccine for elephant endotheliotropic herpesvirus (EEHV). The vaccine successfully saved two vaccinated young elephants at the Cincinnati Zoo.
  • Red 'Ghost' Wolf Cloning & Genetic Rescue Program Cloning of red wolves from blood samples of Gulf Coast 'ghost canids' carrying ancestral red wolf DNA, led by the Colossal Foundation in coalition with the Gulf Coast Canine Project. Clones could add 25% more diversity to red wolf breeding programs.
  • AI-Powered Bioacoustic Monitoring AI-driven bioacoustic monitoring programs deployed in Yellowstone (gray wolves), Samburu (African elephants), and Samoa (tooth-billed pigeon) for passive conservation monitoring, species identification, and behavior analysis.
  • Form Bio Software/wetware/hardware spinout company referenced on Colossal's technology page, part of the platform's commercialization track parallel to the de-extinction focus areas.
  • New World Screwworm Gene Drive Program Gene drive technology engineered to produce infertile female screwworms and spread through wild populations until collapse; proposed as a faster alternative to sterile insect technique for eliminating the flesh-eating parasite that threatens U.S. livestock. Currently unapproved for open release.

Companies that use Colossal Biosciences

Customer profile

Named customers14 records

Segments5 records

Ideal customer profiles5 records

Colossal Biosciences technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature9 records

Colossal Biosciences partnerships and signals

Strategic signal

Partnerships

38 partnerships are on record, tiered flagship, minor and core.

  • U.S. Fish and Wildlife ServiceflagshipStrategic or Co-development Partner · 25 June 2026Partnership with the Colossal Foundation to create a genetic biobank for over 2,300 threatened and endangered species under the Endangered Species Act, with the Colossal Foundation committing $100M+ and making all genomic data freely available via open-access repositories.
  • Colossal FoundationflagshipStrategic or Co-development Partner · 25 June 2026Colossal's nonprofit arm with $100M+ in donations since late 2024, deploying Colossal's technologies to partner-led conservation initiatives including the USFWS BioVault and the Samoa Conservation Society partnership.
  • Quantum XChangeminorChannel Partner/ Reseller/ Distributor · 1 May 2026Colossal listed among Quantum XChange's strategic partners for post-quantum cryptography alongside Copper River, Data Wide, Evolutio, GovSmart, Iron Bow and World Wide Technology.
  • Endangered Wildlife TrustcoreStrategic or Co-development Partner · 30 April 2026South African conservation partner conducting ecological planning, stakeholder engagement and feasibility studies for potential bluebuck reintroduction and broader antelope conservation.
  • Advanced Conservation StrategiescoreImplementation/ SI/ Consulting Partner · 30 April 2026Partner on bluebuck and broader antelope conservation, contributing ecological planning and feasibility work alongside the Endangered Wildlife Trust.
  • Astromech (AI subsidiary)flagshipStrategic or Co-development Partner · 3 April 2026Colossal's AI-focused subsidiary that reached unicorn status with a $2B+ valuation in nine months and raised $10.5M per bizjournals, serving as a commercial AI spinout of Colossal's platform.
  • United Arab Emirates GovernmentflagshipStrategic or Co-development Partner · 3 February 2026Nine-figure partnership (including a $60M investment tranche) to build the Colossal BioVault and World Preservation Lab at Dubai's Museum of the Future, preserving genetic material from over 10,000 species with plans to expand into a global network of 10+ interconnected BioVaults.
  • Viagen Pets & EquineflagshipStrategic or Co-development Partner · 6 November 2025Acquired by Colossal in November 2025 to integrate reproductive services, cryopreservation and cell banking into its conservation platform; operates as a wholly owned subsidiary continuing its pet, equine and livestock services while partnering on endangered-species programs and BioVaults.
  • University of MelbourneflagshipStrategic or Co-development Partner · 21 August 2025Academic partner for the thylacine de-extinction program since 2025 via the new Colossal Australia entity; hosts the TIGRR Lab led by Chief Biology Officer Andrew Pask.
  • Ngāi Tahu Research CentreflagshipStrategic or Co-development Partner · 11 July 2025Strategic partnership directing the South Island giant moa de-extinction program with Peter Jackson and Colossal; the principal Māori research hub of New Zealand's South Island leads rather than merely advises on the project, integrating cultural perspectives.
  • Canterbury MuseumcoreStrategic or Co-development Partner · 11 July 2025Provides access to the world's largest moa bone collection, supplying ancient DNA for the South Island giant moa de-extinction program.
  • Samoa Conservation SocietycoreStrategic or Co-development Partner · 29 May 2025Partner for AI-driven bioacoustic search to find the critically endangered tooth-billed pigeon (manumea) in Samoa; led by the Colossal Foundation.
  • Mauritian Wildlife FoundationcoreStrategic or Co-development Partner · 21 November 2023Partnership to rewild the dodo to its native habitat, with the MWF helping to protect critically-endangered avian species on Mauritius and laying groundwork for the dodo's eventual reintroduction.
  • BioRescueflagshipStrategic or Co-development Partner · 1 September 2023Colossal joined BioRescue in its mission to save the northern white rhino from extinction, sequencing all known viable and preserved museum samples to identify lost genetic diversity that can be engineered into cell lines for embryo transfer.
  • Baylor College of MedicinecoreStrategic or Co-development Partner · 1 July 2023Co-developed the mRNA vaccine for elephant endotheliotropic herpesvirus (EEHV) that saved two young elephants at the Cincinnati Zoo; longstanding academic partner on elephant conservation.
  • Elephant HavenscoreStrategic or Co-development Partner · 1 July 2023Partnership to develop new models for the successful reintroduction of orphaned elephants using AI; the only elephant orphanage in Botswana using Colossal's AI platform.
  • Save the ElephantscoreStrategic or Co-development Partner · 1 January 2023Uses Colossal's AI and drones to study elephants in Samburu National Park, training AI to identify individuals, herds and behaviors and to predict behavior to mitigate Human-Elephant Conflict.
  • Museum of the Future (Dubai)flagshipStrategic or Co-development Partner · 1 January 2023Directed by Sheikh Hamdan bin Mohammed bin Rashid Al Maktoum to become the permanent home of the World Preservation Lab and BioVault, a biotechnology initiative developed in collaboration with Colossal Biosciences.
  • Aussie ArkminorStrategic or Co-development Partner · 1 January 2022Australian conservation partner supporting marsupial conservation and Tasmanian devil reintroduction.
  • RewildminorStrategic or Co-development Partner · 1 January 2022Conservation partner contributing to Tasmanian devil reintroduction into mainland Australia and broader rewilding programs.
  • WildArkminorStrategic or Co-development Partner · 1 January 2022Australian conservation partner supporting Tasmania thylacine and broader biodiversity initiatives; Chris Hemsworth cited WildArk as a partner he is excited to support.
  • Bonorong Wildlife SanctuaryminorStrategic or Co-development Partner · 1 January 2022Tasmanian wildlife sanctuary partner supporting Tasmanian devil conservation and rewilding.
  • Southeast Zoo Alliance for Reproduction & Conservation (SEZARC)minorStrategic or Co-development Partner · 1 January 2022Florida-based reproductive science alliance led by Linda Penfold, contributing expertise in assisted reproduction for endangered species.
  • Pronatura NoroesteminorStrategic or Co-development Partner · 1 January 2022Latin American conservation partner supporting regional biodiversity programs.
  • Yellowstone ForeverminorStrategic or Co-development Partner · 1 January 2022Conservation partner hosting Colossal's AI-powered bioacoustic monitoring program for gray wolves in Yellowstone.
  • BirdLife InternationalminorStrategic or Co-development Partner · 1 January 2022Global avian conservation partner supporting dodo and broader pigeon conservation programs.
  • IUCN SSC Pigeon and Dove Specialist GroupminorStrategic or Co-development Partner · 1 January 2022Specialist conservation partner supporting avian genomics and dodo de-extinction work.
  • International Rhino FoundationminorStrategic or Co-development Partner · 1 January 2022Conservation partner supporting the northern white rhino genetic rescue program.
  • Vertebrate Genomes Project (VGP)minorStrategic or Co-development Partner · 1 January 2022Academic consortium providing reference genome resources for Colossal's comparative genomics and de-extinction programs.
  • Wolf Conservation CenterminorStrategic or Co-development Partner · 1 January 2022Conservation partner for wolf conservation messaging and outreach; also publicly critiqued Colossal's red wolf cloning approach.
  • University of Alaska Fairbanks (Alaska Stable Isotope Facility, Alaska Quaternary Center)minorStrategic or Co-development Partner · 1 January 2022Ancient DNA research partner providing radiocarbon dating and ancient DNA analysis of mammoth and other Pleistocene fossils housed at the University of Alaska Museum of the North.
  • McMaster UniversityminorStrategic or Co-development Partner · 1 January 2022Ancient DNA academic partner receiving Colossal funding for deep-time genomic research on North American Columbian mammoths, Pygmy mammoths and megafauna such as giant ground sloths, glyptodonts and pampatheres.
  • University of Copenhagen (Center for Evolutionary Hologenomics)minorStrategic or Co-development Partner · 1 January 2022Ancient DNA academic partner including high-coverage genomes of extinct species and chromosome-scale assemblies of living relatives, plus research on cave hyenas.
  • Stockholm UniversityminorStrategic or Co-development Partner · 1 January 2022Partner with Professor Love Dalén studying ancient DNA of extinct species including bluebuck, straight-tusked elephant and other recently extinct animals to understand the extinction process.
  • University of PotsdamminorStrategic or Co-development Partner · 1 January 2022Dr. Michael Hofreiter leads Colossal-funded genome sequencing of extinct species such as bluebuck and the straight-tusked elephant at the Institute for Biochemistry and Biology.
  • Rowan University (Edelman Fossil Park & Museum)minorStrategic or Co-development Partner · 1 January 2022Academic partner (Kenneth Lacovara) unlocking ancient proteins and biomolecules from fossils to study extinct creatures.
  • UC Santa Cruz Genomics InstituteminorStrategic or Co-development Partner · 1 January 2022Beth Shapiro-led paleogenomics research partnership, supported by Colossal donations.
  • Cherokee NationminorStrategic or Co-development Partner · 1 January 2022Indigenous partner for red wolf conservation, honoring the cultural and spiritual significance of the wolf as a clan animal.

Scale indicators14 records

Recent moves9 records

Expansion highlights7 records

Colossal Biosciences competitors and assessment

Company assessment

Broad incumbents

  • Twist Bioscience: Synthetic DNA and genomics products company whose DNA synthesis and NGS products underpin much of the synthetic biology ecosystem, including ancient DNA reconstruction pipelines similar to Colossal's reference genome work.
  • CRISPR Therapeutics: Clinical-stage gene editing company co-founded by Emmanuelle Charpentier, applying CRISPR/Cas9 to human therapeutics. A broad incumbent in the same underlying CRISPR platform technology that Colossal uses for de-extinction.
  • Ginkgo Bioworks: Large synthetic biology platform company offering cell engineering and biofoundry services. Comparable to Colossal as a platform biotech commercializing engineered biology, though focused on industrial organisms rather than de-extinction.

Emerging players

  • Recursion Pharmaceuticals: AI-driven biotech combining high-throughput biology with machine learning. Comparable to Colossal's Astromech subsidiary as a biology + AI platform company pursuing large, multi-program pipelines.
  • eGenesis: Gene editing company applying CRISPR to xenotransplantation (gene-edited pig organs for human transplant). Directly comparable on CRISPR platform technology and on the integration of genome editing with reproductive biology.
  • Verve Therapeutics: Clinical-stage gene editing company developing in vivo CRISPR-based cardiovascular therapies. Comparable to Colossal on the underlying CRISPR platform and on its positioning around 'rewriting' biology for a defined outcome.
  • Mammoth Biosciences: CRISPR-based biotech co-founded by Jennifer Doudna developing CRISPR diagnostics and gene-editing therapies. Comparable to Colossal as a CRISPR platform company, though focused on human health rather than animal de-extinction.

Others

  • 23andMe: Consumer genetics company with a large proprietary genotype/phenotype database. Thematically comparable to Colossal in combining large-scale genomics, AI and consumer-facing storytelling, though operating in human rather than animal genetics.
  • Conservation X Labs: Conservation technology incubator and grand-prize challenge sponsor focused on ending the sixth mass extinction. Adjacent to Colossal's mission and a potential partner/customer in conservation tech rather than a direct competitor.

Direct peers

  • Revive & Restore: The leading nonprofit dedicated to de-extinction and genetic rescue, working on the passenger pigeon, northern white rhino, and Przewalski's horse. It is the closest direct peer to Colossal's mission and uses similar CRISPR and ancient DNA tooling.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat7 records

Key risks6 records

Key highlights7 records

Customer concentration

Colossal Biosciences social profiles

Digital presence

Colossal Biosciences financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Colossal Biosciences leadership team

Management profile

Number of profiles

Profiles16 records

Colossal Biosciences subsidiaries and ownership

Company hierarchy

Subsidiaries4 records

Colossal Biosciences funding detail

Funding detail

Funding overview

Funding rounds8 records

Investors33 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Colossal Biosciences M&A and investment

M&A and investment

M&A1 record

Investments3 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Colossal Biosciences

What does Colossal Biosciences do?

Colossal Biosciences is a biotechnology company that uses CRISPR-based genetic engineering, ancient DNA assembly, stem cell reprogramming, and reproductive biology to pursue 'functional de-extinction' of lost species (woolly mammoth, thylacine, dodo, dire wolf, moa, bluebuck) while applying the same toolkit to conservation of living endangered species. It monetizes through government BioVault contracts, conservation technology licensing, the Viagen pet cloning subsidiary, and the Astromech AI spinout.

Is Colossal Biosciences a public or private company?

Colossal Biosciences is a private company. It is classified as venture growth investor backed and is currently operating.

When was Colossal Biosciences founded?

Colossal Biosciences was founded in 2021. It employs 251 to 500 people.

Where is Colossal Biosciences based?

Colossal Biosciences is headquartered in Austin, United States, in the North America region.

How does Colossal Biosciences make money?

Five revenue lines are on record. Commercial Pet Cloning Services are the primary driver. The others are spinout Subsidiary Revenue, government BioVault Contracts, conservation Technology Licensing & Partnerships and venture Funding & Equity Capital.

Who are Colossal Biosciences's main competitors?

Broad incumbents on record are Twist Bioscience, CRISPR Therapeutics and Ginkgo Bioworks. Emerging players are Recursion Pharmaceuticals, eGenesis, Verve Therapeutics and Mammoth Biosciences. Others are 23andMe and Conservation X Labs. Revive & Restore is listed as a direct peer.

Does Colossal Biosciences have an API?

No public API is recorded for Colossal Biosciences.

What industry is Colossal Biosciences in?

Colossal Biosciences's product category is Biotechnology. Its primary akta.pro industry code is HLAAAIAD, Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development), with a secondary code of HLAMANAJ, Cryopreservation, Biobanking & Cell Banking (Cord/Adipose/MSC). Its NAICS code is 541714 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
YahooScientists Say De-Extinction Is Impossible—Because Extinction Isn’t What You Think It IsScientists argue de-extinction is impossible because extinction ends an evolutionary lineage, not just genetic information. They cite Colossal Biosciences' dire wolf announcement as a case of lineage-genome conflation, noting missing ecological context. The authors suggest genomic-assisted breeding for endangered species is more worthwhile.PRESSBEE‘Lord of the Rings’ Director Peter Jackson Helps Bring Rare 2,000-Year-Old Treasure Home ...Saudi ArabiaPeter Jackson partnered with Colossal Biosciences to return a rare giant moa egg to New Zealand after it spent 60 years in a U.S. private collection. The egg, discovered in 1966 and possibly from a 1300 burial site, will be presented to Ngāi Tahu leader Professor Te Maire Tau. A repatriation ceremony is planned for December.Yahoo'Lord of the Rings' Director Peter Jackson Helps Bring Rare 2,000-Year-Old Treasure HomePeter Jackson partnered with Colossal Biosciences to return a rare 2,000-year-old moa egg to New Zealand after it spent 60 years in a U.S. private collection. The egg, discovered in 1966, will be presented to Professor Te Maire Tau, with a repatriation ceremony planned for December.YahooHere's Why The Dire Wolf Really Wasn't Brought Back From Extinction, Scientists ArgueResearchers argue that Colossal Biosciences' 2025 genetic edits to grey wolves, producing dire wolf traits, are not de-extinction. They call it lineage-genome conflation, noting extinction ends evolutionary lineages. They suggest preserved cells or embryos are more promising for true de-extinction.New York PostTop scientist stole trade secrets from startup that wants to bring back extinct species: bombshell suitColossal Biosciences sued former VP James Kehler in Texas federal court, alleging he stole trade secrets and shared them with competitors. The suit claims he moved confidential files to personal devices before leaving for rival labs. Colossal seeks damages, citing its $200 million funding round and $10.2 billion valuation.YahooColossal is using a new AI-platform to help bring back the dodoColossal Biosciences announced its GenoMorph AI platform on Oct. 14 to aid dodo de-extinction. The software identified about 2,300 DNA regions linked to beak shape, using data from over 70 bird species. These regions will guide future gene-editing experiments.EstadaoEmpresa quer criar cães militares geneticamente modificadosWarhound, a startup formed by Anduril and Colossal Biosciences, plans to create genetically modified military dogs for US armed forces, with $200 million in funding. The dogs will perform bomb detection and rescue tasks, with the first litter expected in early 2027. The company expects to sell them to police, emergency teams, and the US Department of Defense.PR NewswireWarhound Launches with $200 Million to Rebuild America's Military Working Dog Supply, Using Advanced Genetics and Defense TechnologyWarhound, founded by Ben Lamm and Palmer Luckey, emerged from stealth with a $200 million seed round to rebuild the U.S. military working dog supply. The company will use Colossal's genetics and Anduril's cybernetic augments, aiming to reduce reliance on European breeders. It is backed by In-Q-Tel, Sequoia, and others.GizmodoPalmer Luckey Is Getting Into the Cybernetically Outfitted Super Soldier Dog MarketWarhound, a Texas-based startup, emerged from stealth with $200 million in seed funding to create genetically modified, cybernetically outfitted military dogs. The company partners with Anduril and Colossal Biosciences, aiming to reduce U.S. dependence on Europe's 80% of working military dogs.